Xencor Inc
NASDAQ:XNCR
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
15.7
26.52
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one XNCR stock under the Base Case scenario is 16.61 USD. Compared to the current market price of 23.71 USD, Xencor Inc is Overvalued by 30%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Xencor Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for XNCR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Xencor Inc
Balance Sheet Decomposition
Xencor Inc
Current Assets | 573.3m |
Cash & Short-Term Investments | 543m |
Receivables | 10.2m |
Other Current Assets | 20.1m |
Non-Current Assets | 410.3m |
Long-Term Investments | 290.3m |
PP&E | 101.2m |
Intangibles | 17.9m |
Other Non-Current Assets | 883k |
Current Liabilities | 92m |
Accounts Payable | 18.8m |
Accrued Liabilities | 27.6m |
Other Current Liabilities | 45.6m |
Non-Current Liabilities | 167.8m |
Long-Term Debt | 10.2m |
Other Non-Current Liabilities | 157.7m |
Earnings Waterfall
Xencor Inc
Revenue
|
85.2m
USD
|
Operating Expenses
|
-302.6m
USD
|
Operating Income
|
-217.5m
USD
|
Other Expenses
|
19.2m
USD
|
Net Income
|
-198.2m
USD
|
Free Cash Flow Analysis
Xencor Inc
USD | |
Free Cash Flow | USD |
In 2023, Xencor emphasized its T-cell engagers, particularly vudalimab for prostate and lung cancer, reducing investment in cytokine candidates. Its XmAb platform was validated by Amgen's data, and collaborative CD28 bispecific trials began with J&J, underscoring strong partnerships. A strategic royalty monetization significantly enhanced its balance sheet, resulting in a robust $697 million ending cash balance. Xencor now anticipates a financial runway extending into 2027.
What is Earnings Call?
XNCR Profitability Score
Profitability Due Diligence
Xencor Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
Score
Xencor Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
XNCR Solvency Score
Solvency Due Diligence
Xencor Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Score
Xencor Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XNCR Price Targets Summary
Xencor Inc
According to Wall Street analysts, the average 1-year price target for XNCR is 35.29 USD with a low forecast of 20.2 USD and a high forecast of 61.95 USD.
Dividends
Current shareholder yield for XNCR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
XNCR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Xencor, Inc. is biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Monrovia California, California and currently employs 254 full-time employees. The company went IPO on 2013-12-03. The firm is advancing a portfolio of clinical-stage XmAb drug candidates from its protein engineering technology platforms. The firm uses its engineering capabilities to enable its understanding of protein structure and interactions to design technologies and XmAb development candidates with properties. The company is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Tidutamab, XmAb841, XmAb306, AMG 509, XmAb819, XmAb104, XmAb564 and Novartis XmAb.
Contact
IPO
Employees
Officers
The intrinsic value of one XNCR stock under the Base Case scenario is 16.61 USD.
Compared to the current market price of 23.71 USD, Xencor Inc is Overvalued by 30%.